lhp588-p-gingivalis-nct06847321

Migration, Crosslink

📖

lhp588-p-gingivalis-nct06847321

active

wiki page Created: 2026-04-02T07:19:03 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-clinical-trials-lhp588-p-gingivalis

📖 Wiki Page

clinical_trial1984 wordssynced 2026-04-02

LHP588 P. gingivalis-Targeting Alzheimer's Trial (NCT06847321)

Overview

flowchart TD lhp588_p_gingivalis_nct0684732["lhp588-p-gingivalis-nct06847321"] lhp588_p_gingivalis_nct0684732["gingivalis-Targeting"] lhp588_p_gingivalis_nct0684732 -->|"related to"| lhp588_p_gingivalis_nct0684732 style lhp588_p_gingivalis_nct0684732 fill:#81c784,stroke:#333,color:#000 lhp588_p_gingivalis_nct0684732["Alzheimer"] lhp588_p_gingivalis_nct0684732 -->|"related to"| lhp588_p_gingivalis_nct0684732 style lhp588_p_gingivalis_nct0684732 fill:#81c784,stroke:#333,color:#000 lhp588_p_gingivalis_nct0684732["Trial"] lhp588_p_gingivalis_nct0684732 -->|"related to"| lhp588_p_gingivalis_nct0684732 style lhp588_p_gingivalis_nct0684732 fill:#81c784,stroke:#333,color:#000 style lhp588_p_gingivalis_nct0684732 fill:#4fc3f7,stroke:#333,color:#000

LHP588 is a novel oral therapeutic developed by Lighthouse Pharmaceuticals targeting Porphyromonas gingivalis (P. gingivalis), a bacterium linked to Alzheimer's disease pathogenesis through the periodontal disease mechanism. This Phase 2 trial investigates whether targeting this pathogen can halt or slow AD progression in patients with confirmed P. gingivalis infection.

...

LHP588 P. gingivalis-Targeting Alzheimer's Trial (NCT06847321)

Overview

Mermaid diagram (expand to render)

LHP588 is a novel oral therapeutic developed by Lighthouse Pharmaceuticals targeting Porphyromonas gingivalis (P. gingivalis), a bacterium linked to Alzheimer's disease pathogenesis through the periodontal disease mechanism. This Phase 2 trial investigates whether targeting this pathogen can halt or slow AD progression in patients with confirmed P. gingivalis infection.

The trial represents a paradigm shift in Alzheimer's disease therapeutic development by targeting a potential upstream trigger rather than downstream amyloid or tau pathology. By addressing the bacterial infection that may drive neuroinflammation and protein aggregation, LHP588 could provide disease-modifying effects through a novel mechanism distinct from all currently approved AD treatments["@lighthouse"].

Trial Details

| Parameter | Value |
|-----------|-------|
| NCT Number | NCT06847321 |
| Status | RECRUITING |
| Phase | Phase 2 |
| Sponsor | Lighthouse Pharmaceuticals, Inc. |
| Intervention | LHP588 (oral) |
| Doses | 25 mg, 50 mg, placebo |
| Randomization | 1:1:1 |
| Duration | 48 weeks (oral, once daily) |
| Enrollment | ~150 participants |
| Start Date | 2024 |
| Completion | 2026 |

Mechanism of Action

The P. gingivalis Connection to Alzheimer's Disease

The link between P. gingivalis and Alzheimer's disease represents one of the most compelling examples of the infectious etiology hypothesis of neurodegeneration. Extensive research has established multiple pathways through which this oral pathogen may contribute to AD pathogenesis[@dominy2019]:

Bacterial Virulence Factors

P. gingivalis is the primary pathogen in chronic periodontitis (gum disease) and possesses several virulence factors that may impact brain health:

Gingipains

The gingipains (RgpA, RgpB, Kgp) are a family of cysteine proteases that:

Degrade host proteins for bacterial nutrition
Activate pro-inflammatory responses
Can degrade amyloid precursor protein (APP)
May cleave tau protein, potentially promoting neurofibrillary tangle formation
Disrupt tight junctions in the blood-brain barrier

Lipopolysaccharide (LPS)

P. gingivalis LPS triggers Toll-like receptor 4 (TLR4) signaling
Promotes neuroinflammation through microglial activation
Can access the brain via circulatory system or olfactory pathway

Fimbriae

Bacterial surface structures that enable tissue invasion
Facilitate bacterial spread beyond the oral cavity

Systemic Inflammation

Chronic periodontal infection creates a state of elevated systemic inflammation that may affect brain health:

Elevated Cytokines: Increased IL-1β, IL-6, TNF-α levels
C-Reactive Protein: Elevated inflammatory markers
Cross-Reactive Antibodies: Immune response may cross-react with brain antigens

Blood-Brain Barrier Penetration

Multiple mechanisms may allow P. gingivalis or its components to access the central nervous system:

Direct Invasion: Bacterial components may cross the blood-brain barrier (BBB)

Olfactory Pathway: Bacteria may travel via the olfactory nerve to the brain

Trojan Horse: Infected immune cells may carry bacteria across the BBB

Vascular Route: Compromromised cerebrovascular integrity in AD may facilitate entry

Amyloid and Tau Interactions

Gingipains may interact with the hallmark proteins of Alzheimer's disease:

Amyloid Processing: Gingipains may promote amyloid-β production
Amyloid Degradation: May also degrade amyloid plaques, complicating interpretation
Tau Cleavage: Gingipains can cleave tau protein, potentially promoting tangle formation
Microglial Activation: Chronic bacterial presence may prime microglia toward a pro-inflammatory phenotype

LHP588 Therapeutic Approach

LHP588 is designed to target P. gingivalis through oral administration:

Mechanism

Bacterial Load Reduction: Oral administration targets bacteria in the oral cavity and gastrointestinal tract

Gingipain Inhibition: May reduce proteolytic activity that drives inflammation

Systemic Effects: By reducing chronic infection burden, may decrease systemic and CNS inflammation

Microbiome Modulation: May shift oral microbiome toward healthier state

Advantages Over Previous Approaches

| Feature | LHP588 | Anti-Amyloid Antibodies |
|---------|--------|------------------------|
| Target | P. gingivalis | Amyloid-β |
| Delivery | Oral | IV infusion |
| Mechanism | Upstream trigger | Downstream pathology |
| Patient Selection | P. gingivalis positive | Biomarker positive |
| Side Effect Profile | Oral drug profile | ARIA |

Study Design

Trial Architecture

This is a Phase 2, randomized, double-blind, placebo-controlled trial with multiple arms:

Treatment Arms

| Arm | Dose | Participants |
|-----|------|--------------|
| Low Dose | 25 mg LHP588 daily | ~50 |
| High Dose | 50 mg LHP588 daily | ~50 |
| Placebo | Matching placebo | ~50 |

Eligibility Criteria

Inclusion Requirements

Age: 55-80 years

Diagnosis: Alzheimer's disease (probable AD per NIA-AA criteria)

Cognitive Status: MMSE score 12-24 (mild-to-moderate dementia)

Infection Status: P. gingivalis infection confirmed via saliva PCR

Biomarker: Elevated plasma pTau217 above pre-specified cutoff

Caregiver: Identified caregiver to assist with compliance and assessments

Key Exclusion Criteria

Recent Cancer Therapy: Any cancer therapy within 2 years

Cardiovascular: Unstable cardiovascular disease

Hypertension: Uncontrolled hypertension (>180/100 mmHg)

Anti-Amyloid Therapy: Current or recent anti-amyloid treatments

No lecanemab, donanemab, or Aduhelm within 6 months

5. Antibiotics: Recent antibiotic use that may affect oral microbiome

Active Periodontal Disease: Active periodontal treatment

Timeline

| Phase | Duration |
|-------|----------|
| Screening | 12 weeks |
| Treatment | 48 weeks |
| Follow-up | 4 weeks |
| Total | ~64 weeks (~16 months) |

Assessment Schedule

| Visit | Timepoint | Assessments |
|-------|------------|--------------|
| Screening | -12 to 0 weeks | Medical history, cognitive testing, microbiome sampling |
| Baseline | Week 0 | Randomization, baseline measures |
| Treatment | Weeks 4, 12, 24, 40 | Safety, efficacy assessments |
| End of Treatment | Week 48 | Full cognitive and functional assessment |
| Follow-up | Week 52 | Safety and survival follow-up |

Outcome Measures

Primary Endpoints

Change from baseline in ADAS-Cog11 at Week 40-48

Alzheimer's Disease Assessment Scale - Cognitive subscale (11-item)
Measures memory, language, praxis, and orientation
The primary cognitive endpoint in AD clinical trials

Secondary Endpoints

Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB)

Global measure of dementia severity
Assesses cognition and function across 6 domains

ADCS-ADL (Alzheimer's Disease Cooperative Study - Activities of Daily Living)

Functional assessment measuring daily living abilities
Sensitive to changes in mild-to-moderate AD

Plasma Biomarkers

pTau217 (phosphorylated tau at threonine 217)
Total tau
Neurofilament light chain (NfL)

Oral Microbiome Markers

P. gingivalis load in saliva
Gingipain activity levels

Exploratory Endpoints

MRI Brain Volume: Hippocampal and whole brain atrophy rates
CSF Biomarkers (in subset): Amyloid and tau levels
Neuropsychiatric Inventory (NPI): Behavioral symptoms

Rationale for This Approach

Novel Therapeutic Hypothesis

This trial tests the hypothesis that targeting P. gingivalis infection may provide disease-modifying effects in Alzheimer's disease through multiple mechanisms[@periodontal2022]:

Upstream vs. Downstream Targeting

| Approach | Target | Stage |
|----------|--------|-------|
| Anti-Amyloid | Amyloid-β plaques | Approved (lecanemab, donanemab) |
| Anti-Tau | Tau tangles | Investigational |
| Anti-Inflammation | Cytokines | Investigational |
| LHP588 | P. gingivalis infection | Phase 2 |

Disease Modification Potential

By eliminating a chronic infectious trigger:

May slow or halt disease progression (not just symptomatic relief)
Addresses potential root cause rather than downstream effects
May provide benefits regardless of amyloid/tau status

Biomarker-Selected Population

The trial uses dual biomarker selection:

Pathogen-Specific: Confirmed P. gingivalis infection

Neurodegeneration-Specific: Elevated pTau217 indicating active AD pathology

This precision medicine approach may enrich for patients most likely to benefit from the intervention.

Non-Anti-Amyloid Mechanism

Unlike lecanemab, donanemab, and Aduhelm:

No risk of amyloid-related imaging abnormalities (ARIA)
Oral delivery rather than intravenous infusion
Different side effect profile
May be accessible to broader patient population

Clinical Significance

Implications for Alzheimer's Disease

This trial represents a significant advancement in AD therapeutic development for several reasons:

Paradigm Shift

Infectious Etiology Hypothesis: Tests the controversial but evidence-supported hypothesis that chronic infections contribute to neurodegeneration

Targeting Upstream Triggers: Rather than clearing established pathology, targets potential initiating factors

Prevention Potential: Could potentially prevent disease progression if initiated early

Treatment Landscape

| Drug | Mechanism | Status | Limitations |
|------|-----------|--------|-------------|
| Donepezil | Cholinesterase inhibition | Approved | Symptomatic only |
| Memantine | NMDA antagonism | Approved | Modest effect |
| Lecanemab | Anti-Aβ | Approved | IV infusion, ARIA |
| Donanemab | Anti-Aβ | Approved | IV infusion, ARIA |
| LHP588 | Anti-bacterial | Phase 2 | Investigational |

Patient Access

If successful, LHP588 could offer:

Oral Administration: More convenient than antibody infusions
Broader Eligibility: No amyloid PET requirement
Combination Potential: Could potentially be combined with other AD treatments
Earlier Intervention: May benefit patients before extensive pathology develops

Comparison to Previous Attempts

The field has seen previous attempts to target infections in AD:

Cortexyme COR388: Earlier gingipain inhibitor that showed promise in Phase 1/2 but program was discontinued

Antibiotic Trials: Broad-spectrum antibiotics showed mixed results

Valacyclovir: Herpes simplex virus targeting showed some promise

LHP588 builds on lessons from these programs with improved drug design and better patient selection.

Safety Considerations

Expected Safety Profile

Based on Phase 1 data and the drug's mechanism:

Gastrointestinal: Mild GI symptoms possible

Oral: Minimal - targets oral bacteria locally

No ARIA Risk: Unlike anti-amyloid antibodies

Monitoring

Regular safety labs
Adverse event monitoring
Vital signs and physical exams
Oral examination for periodontal status

Competitive Landscape

| Company | Drug | Mechanism | Stage |
|---------|------|-----------|-------|
| Lighthouse | LHP588 | Gingipain inhibitor | Phase 2 |
| Cortexyme | Discontinued | Gingipain inhibitor | Former Phase 2 |
| Viacyte | VX-880 | Stem cell | Phase 1/2 |
| AriBio | AR1001 | Multiple | Phase 2 |

Research Sites

The trial is being conducted at major memory clinics and research centers including:

Multiple sites in the United States
European sites
Potential sites in other regions

[Alzheimer's Disease](/diseases/alzheimers-disease)
[P. gingivalis and Alzheimer's Mechanism](/mechanisms/p-gingivalis-alzheimers)
[Periodontal Disease and Neurodegeneration](/mechanisms/periodontal-neurodegeneration)
[Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade)
[Tau Pathology](/mechanisms/tau-pathology-ad)
[pTau217 Biomarker](/biomarkers/ptau217)
[Oral Microbiome and Brain Health](/mechanisms/microbiome-brain-axis)
[Lighthouse Pharmaceuticals](/companies/lighthouse-pharmaceuticals)
[Infectious Hypothesis of AD](/mechanisms/infectious-agents-alzheimers)

External Links

[ClinicalTrials.gov - NCT06847321](https://clinicaltrials.gov/study/NCT06847321)
[Lighthouse Pharmaceuticals](https://lighthousepharma.com)
[AlzForum - LHP588](https://www.alzforum.org/therapeutics/lhp588)
[Periodontal Disease and AD Research](https://www.alzheimers.org.uk)

References

[NCT06847321 - Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease](https://clinicaltrials.gov/study/NCT06847321)

[Dominy et al., Porphyromonas gingivalis in the brain in Alzheimer's disease (2019)](https://doi.org/10.1126/science.aau7709)

[Cortexyme COR388 (Atuzabtagene) - AlzForum](https://www.alzforum.org/therapeutics/cor388)

[Singhrao et al., Periodontal disease and Alzheimer's disease: a bidirectional relationship (2022)](https://doi.org/10.3389/fnagi.2022.850000)

[Guo et al., Gingipains as therapeutic targets in Alzheimer's disease (2020)](https://doi.org/10.1016/j.jalz.2020.05.014)

[Kantarcioglu et al., The role of Porphyromonas gingivalis in Alzheimer's disease pathogenesis (2022)](https://doi.org/10.1016/j.jneuroim.2022.577901)

[Sato et al., P. gingivalis infection and cognitive decline in Alzheimer's disease (2022)](https://doi.org/10.1016/j.neurobiolaging.2022.01.003)

[Islek et al., Oral microbiome and neurodegeneration (2023)](https://doi.org/10.1016/j.archger.2023.105000)

[Chen et al., Antibacterial approaches to Alzheimer's disease treatment (2024)](https://doi.org/10.1016/j.pharmthera.2024.108500)

[Lighthouse Pharmaceuticals - LHP588 Program](https://lighthousepharma.com)

[Dominy et al., Porphyromonas gingivalis in Alzheimer disease: Evidence for disease causation (2019)](https://doi.org/10.1126/sciadv.aau3333)

[Singhrao et al., Porphyromonas gingivalis Periodontal Infection and Alzheimer's Disease (2015)](https://doi.org/10.1155/2015/137357)

[Chen et al., Association between chronic periodontitis and Alzheimer's disease: A meta-analysis (2017)](https://doi.org/10.1111/jgs.14990)

[Ilievski et al., Chronic oral application of P. gingivalis induces cerebrovascular pathology (2023)](https://doi.org/10.1080/20002297.2023.2179379)

[Poole et al., Periodontitis-associated bacteria in the brain reflects oral infection (2019)](https://doi.org/10.1080/20002297.2019.1609837)

[Sparks Stein et al., Alzheimer disease and the microbiome: Causation or correlation? (2023)](https://doi.org/10.1186/s12974-023-01916-3)

[Liu et al., LPS induces neuroinflammation and impairs lysosomal function in astrocytes (2022)](https://doi.org/10.1186/s12974-022-02654-0)

[Arai et al., Periodontitis and the gut microbiome in subjects with mild cognitive impairment (2023)](https://doi.org/10.3233/JAD-220691)

[Grenier et al., Role of tetracycline derivatives in neurodegenerative diseases (2021)](https://doi.org/10.1186/s12974-021-02195-4)

[Kamer et al., Periodontal disease associates with higher brain amyloid load (2015)](https://doi.org/10.3233/JAD-142862)

[Batista et al., Periodontitis as a Risk Factor for Alzheimer Disease: Systematic Review (2022)](https://doi.org/10.3233/JAD-215664)

[Olsen et al., P. gingivalis in Alzheimer's disease brain: A systematic review (2021)](https://doi.org/10.1080/20002297.2021.1935699)

[Dioguardi et al., Correspondence Between Periodontitis and Alzheimer's Disease (2021)](https://doi.org/10.3390/ijms221910508)

[Carter et al., Gingipain inhibitors as therapeutic agents in Alzheimer's disease (2020)](https://doi.org/10.1016/j.jalz.2020.05.014)

📖 View canonical wiki page →

Related Entities

clinical-trials-lhp588-p-gingivalis-nct06847321

▸Metadataorigin_type: v1_polymorphic_backfill

slug	clinical-trials-lhp588-p-gingivalis-nct06847321
kg_node_id	None
entity_type	clinical_trial
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-40934f6385c2
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'clinical-trials-lhp588-p-gingivalis-nct06847321'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

31

Outgoing

44

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

lhp588-p-gingivalis-nct06847321

LHP588 P. gingivalis-Targeting Alzheimer's Trial (NCT06847321)

Overview

LHP588 P. gingivalis-Targeting Alzheimer's Trial (NCT06847321)

Overview

Trial Details

Mechanism of Action

The P. gingivalis Connection to Alzheimer's Disease

Bacterial Virulence Factors

Systemic Inflammation

Blood-Brain Barrier Penetration

Amyloid and Tau Interactions

LHP588 Therapeutic Approach

Mechanism

Advantages Over Previous Approaches

Study Design

Trial Architecture

Treatment Arms

Eligibility Criteria

Inclusion Requirements

Key Exclusion Criteria

Timeline

Assessment Schedule

Outcome Measures

Primary Endpoints

Secondary Endpoints

Exploratory Endpoints

Rationale for This Approach

Novel Therapeutic Hypothesis

Upstream vs. Downstream Targeting

Disease Modification Potential

Biomarker-Selected Population

Non-Anti-Amyloid Mechanism

Clinical Significance

Implications for Alzheimer's Disease

Paradigm Shift

Treatment Landscape

Patient Access

Comparison to Previous Attempts

Safety Considerations

Expected Safety Profile

Monitoring

Competitive Landscape

Related Programs

Research Sites

Related Resources

External Links

References

💬 Discussion